Core Viewpoint - 百诚医药 has entered into a collaboration agreement with Zhejiang Zhongshen Innovation Pharmaceutical Technology Co., Ltd. for the development of the BIOS-0629 project, indicating a strategic partnership aimed at enhancing product development and market reach in the Greater China region [1] Group 1: Collaboration Details - The collaboration involves 百诚医药 being responsible for research and development, clinical trials, and registration applications for the product [1] - 浙江众神创新 will handle R&D transformation, production, sales, and market expansion in the Greater China region [1] Group 2: Financial Terms - The total transaction price for the collaboration is set at RMB 300 million [1] - Payment will be made in milestone payments of RMB 300 million upon reaching specific R&D milestones after the contract is signed [1] - Additionally, 百诚医药 will receive a 10% commission on sales revenue from the product once it is launched in the Greater China market [1]
百诚医药就BIOS-0629项目签署技术开发合作协议